ACAD Stock Analysis: Buy, Sell, or Hold?
ACAD - Acadia Pharmaceuticals Inc.
$21.07
0.32 (1.54%)
▲
5d:
+0.38%
30d:
-14.21%
90d:
-23.71%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
ACAD is down 5.8% this week, but smart money is accumulating calls. Top strike: $25 2026-04-17 with 10 OI. Call ratio: 100% View Scanner →
Strength: 7.9/10
Get Alerted When ACAD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ACAD appears deeply undervalued. Market expects -8.1% annual earnings decline despite 86% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: ACAD appears deeply undervalued. Market expects -8.1% annual earnings decline despite 86% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$44.04
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$27.35
22.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ACAD is currently trading at $21.07, which is considered slightly low relative to its 30-day fair value range of $20.84 to $23.81. From a valuation perspective, the stock is trading at a discount (Forward PE: 22.9) compared to its historical average (29.6). Remarkably, the market is currently pricing in an annual earnings decline of 8.1% over the next few years. This pessimistic expectation contrasts with the company's recent 86.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ACAD is in a downtrend. Immediate support is located at $19.89, while resistance sits at $22.36.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $31.85 (+53.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACAD is in a downtrend. Immediate support is located at $19.89, while resistance sits at $22.36.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $31.85 (+53.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$20.84 -
$23.81
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 53.5% below Wall St target ($31.85)
Fair Price Analysis
30-Day Fair Range
$20.84 -
$23.81
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$19.89
Resistance Level
$22.37
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.94
Wall Street Target
$31.85
(+53.5%)
Revenue Growth (YoY)
9.4%
Earnings Growth (YoY)
86.2%
Profit Margin
36.5%
Valuation Discount vs History
-8.1% cheaper
PE vs Historical
22.9 vs 29.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.1%
(market-implied from PE analysis)
1-Year Target
$19.07
(-8%)
2-Year Target
$17.52
(-16%)
3-Year Target
$16.11
(-22%)
3-Yr Target (if PE normalizes)
(PE: 23→30)
$20.78
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.9, Growth: 82.2%)
$70.03
(+238%)
Base:
(SPY PE: 22.4, Growth: 82.2%)
$68.39
(+230%)
Bear:
(PE: 19.0, Growth: 82.2%)
$58.13
(+180%)
📈
Valuation based on Current Earnings
Trailing PE: 9.02 | Current EPS (TTM): $2.30
Bull Case
$11.41
(-46%)
Analyst growth -50.0%, PE expands to 9.9
Base Case
$10.37
(-51%)
Market implied -50.0%, PE stable at 9.0
Bear Case
$14.10
(-33%)
Severe decline -20.0%, PE contracts to 7.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 22.9 to 29.6
Stabilization Target:
$26.78
(+29.0%)
PE Expansion Potential:
+29.0%
Share & Embed Analysis
Last updated: March 30, 2026 4:30 PM ET
Data refreshes hourly during market hours. Next update: 5:30 PM
Data refreshes hourly during market hours. Next update: 5:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACAD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Jennifer J Rhodes
SELL
6950 shares
2026-02-09
James Kihara
SELL
4084 shares
2025-11-18
Mark C Schneyer
SELL
10262 shares
2025-11-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 57 HOLD |
Advanced ACAD Option Strategies
Professional options setups generated by AI based on today's ACAD price and gamma walls.
